Navigating Myelosuppression in Small Cell Lung Cancer

The management of extensive-stage small cell lung cancer (ES-SCLC) remains a clinical tightrope, balancing the necessity of aggressive systemic therapy against the high risk of treatment-induced complications. While the combination of platinum-based chemotherapy and immune checkpoint inhibitors has redefined the standard of care, the threat of chemotherapy-induced myelosuppression (CIM) looms large, often manifesting as life-threatening febrile neutropenia.

During a live Case-Based Roundtable, Mohamed K. Mohamed, MD, PhD, Cone Health Cancer Center, discussed the strategic use of prophylactic measures to mitigate these risks. From the established protocols for granulocyte colony-stimulating factor (G-CSF) to the evolving role of trilaciclib (Cosela), a first-in-class CDK4/6 inhibitor designed to preserve hematopoietic stem cell function.

This is part 2 of a 2-part series.

Register today to join a Case-Based Roundtable near you.

CASE DESCRIPTION

• A 51-year-old woman presented to the emergency department with coughing, chest pain, and dyspnea.
• Past medical history: Thyroidectomy 5 years ago due to thyroid papillary carcinoma with subsequent long-term maintenance therapy with levothyroxine
• 20 pack-year history of smoking
• Physical examination: Thyroid deficiency, otherwise unremarkable
• Chest CT shows a 1.5 cm x 1 cm mass on the right pleural side, associated with pleural thickening and adhesion and scattered satellite lesions; a minimal right pleural effusion; several mediastinal lymph nodes (largest measuring 1 cm x 1.8 cm; pericardial effusion); no evident anomalies in the left thoracic cavity
• Fine-needle aspiration biopsy of the tumor confirms small cell lung cancer
• Imaging shows no signs of distant metastasis
• Carboplatin/etoposide/atezolizumab (Tecentriq) is initiated

Two weeks after receiving the first cycle:

• Patient calls the office to report chest pain and productive cough with fever
• Lab work, imaging, and blood/sputum cultures confirm febrile neutropenia with sepsis in the presence of pneumonia

Targeted Oncology: What would your course of action be for this patient?

Mohamed K. Mohamed, MD, PhD: For a patient like this, I would have them in the hospital for several days, up to a week or so. Even if they have no fever for 24 hours, I would still wait for their counts to recover. Most of the hospitalists who are managing our patients right now are probably not going to allow the patient to leave before she has normal counts of everything.

What are the recommendations for using G-CSF for patients like this?

With any regimen with a neutropenia risk of 20% or higher, you can use prophylactic G-CSF from cycle 1 without waiting.¹ For intermediate risk, 10% to 20%, G-CSF can be used if the patient has 1 or more risk factors. These are age, previous chemotherapy, or other comorbidities. If you have no risk for neutropenia, then we don’t allow G-CSF prophylaxis from the beginning unless the patient develops neutropenia during that first cycle. Then, you could use prophylactic G-CSF on the second cycle.

G-CSF’s mechanism of action is mainly the demarginalization of the preferred blood neutrophils, and it also accelerates the maturation of the hematopoietic stem cells to neutrophils. That’s the benefit of the drug when you give it to the patient.

What are the NCCN guidelines regarding the use of trilaciclib as a prophylactic treatment?

The NCCN guidelines added chemotherapy-induced myelosuppression prophylaxis with trilaciclib before platinum/etoposide with or without an immune checkpoint inhibitor–containing regimen or before a topotecan-containing regimen for ES-SCLC.

Does that recommendation extend to extrapulmonary, fully differentiated neuroendocrine carcinomas?

I don’t think it’s really covered under that. But if your pathologist said it was suspicious for SCLC, then yes. If they call it large cell neuroendocrine carcinoma, probably not.

Are there long-term benefits to using trilaciclib here?

Whenever you use trilaciclib for chemotherapy-induced myelosuppression, you are actually maintaining the bone marrow quality for the future because it doesn’t get destroyed, especially if you start from cycle 1. If you have to start treatment without trilaciclib, you are already destroying some of the hematopoietic stem cells. But if you start from cycle 1, you are maintaining that bone marrow quality for a long time.

Are there any contraindications to trilaciclib?

The contraindications may be allergic reaction or hypersensitivity. Most of our patients have central lines, so infusion-site reactions are probably not a big deal. If somebody has a peripheral line and gets an infusion-site reaction, that’s sometimes concerning. It happened to me when I started using trilaciclib. We didn’t know too much about it, so our nurses would usually flush the line and follow the protocol if the patient had inflammation in their vein, and it worked fine. You need to make sure that your nurses flush the line very well after administration.

How far in advance do you give trilaciclib?

It’s best within 4 hours, but you can give it at any time. We can give it half an hour before starting [chemotherapy]. Most of the patients, they come to the office, they start their infusion, they get trilaciclib, and then they get their chemotherapy. But it has to be done within 28 hours, because the half-life of trilaciclib is 14 hours. So, for example, if you give somebody their first dose of trilaciclib at 8 am on Monday, and then you schedule them for chemotherapy on Tuesday at 4 or 5 pm, that’s more than 28 hours.

REFERENCE

1. Prevention and treatment of cancer-related infections. NCCN Guidelines. Updated 2024. Accessed April 9, 2026.